Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal Insulin With or Without Metformin

NCT03529123 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03529123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03529123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal Insulin With or Without Metformin
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 19, 2018
Completion date
November 25, 2019
Enrollment
247 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus